DrugPatentWatch Database Preview
Details for Patent: 6,017,922
Which drugs does patent 6,017,922 protect, and when does it expire?
This patent has six patent family members in six countries.
Summary for Patent: 6,017,922
Title: | Thermally stable trimetrexates and processes for producing the same |
Abstract: | The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P1(#2) and having a triclinic cell with dimensions of about a=7.699 .ANG., b=9.606 .ANG. and c=13.012 .ANG. is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline , is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form. |
Inventor(s): | Stogniew; Martin (Blue Bell, PA), Grafe; Ingomar (Nurnberg, DE), Morsdorf; Johann (Langenzenn, DE) |
Assignee: | U.S. Bioscience, Inc. (Conshohocken, PA) |
Application Number: | 09/080,290 |
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 6,017,922
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-002 | Jul 31, 1998 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 6,017,922
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
6,258,952 | Thermally stable trimetrexates and processes for producing the same | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 6,017,922
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Japan | 2002515493 | ➤ Try a Free Trial | |||
European Patent Office | 1080079 | ➤ Try a Free Trial | |||
Canada | 2333274 | ➤ Try a Free Trial | |||
Brazil | 9910543 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |